retatrutide 2025 trial results Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a Phase III retatrutide study demonstrates

This is important because rapid IV administration can lead to sudden shifts in electrolytes particularly potassium which may result in hypokalemia and, in severe cases, cardiac complications

When the rise in GLP-1 drugs is reported as the No

weight loss (Phase 2/3 peak) | ~15% | ~22% | ~24% | | FDA Status | Approved (Wegovy, Ozempic) | Approved (Zepbound, Mounjaro) | Phase 3 (2026) | | Dosing frequency | Weekly | Weekly | Weekly | The additional glucagon receptor agonism is believed to be responsible for retatrutide's greater metabolic rate increase and enhanced fat oxidation compared to dual agonists

Summary Though alpha-lipoic acid has properties that may promote weight loss, its overall effect in humans seems negligible

Global sensitivity of structural variability by random sampling